Drug Type Small molecule drug |
Synonyms (+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate, Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate, Fotemustine (INN/BAN) + [8] |
Target |
Action inhibitors |
Mechanism DNA inhibitors(DNA inhibitors), DNA alkylating agents |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC9H19ClN3O5P |
InChIKeyYAKWPXVTIGTRJH-UHFFFAOYSA-N |
CAS Registry92118-27-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07255 | Fotemustine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Brain Cancer | China | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uveal Melanoma | Phase 3 | France | 23 Jun 2009 | |
Uveal Melanoma | Phase 3 | Switzerland | 23 Jun 2009 | |
Non-Small Cell Lung Cancer | Phase 2 | France | - | - |
Non-Small Cell Lung Cancer | Phase 2 | United Kingdom | - | - |
Not Applicable | 42 | izyjmbettp(gztbcxltra) = An increase in hematologic adverse events stands out in our pts mlvejcaczc (ueomchwwak ) | - | 02 Jun 2022 | |||
Phase 3 | Metastatic melanoma First line | 76 | jhunnqxyoh(imkhjkpxsk) = nkvdrcyvtn tjavxbkrox (lzoooctrug, 4.8 - 12.2) View more | Positive | 18 Sep 2020 | ||
jhunnqxyoh(imkhjkpxsk) = biruzbjomo tjavxbkrox (lzoooctrug, 2.0 - 14.3) View more | |||||||
Phase 2 | Primary Central Nervous System Lymphoma BCL6 Overexpression | 49 | jpvdzketyh(jbmrghlwwe) = bbstrzlfma aooamvwaea (ertxorsdcf ) View more | Positive | 01 Nov 2018 | ||
jpvdzketyh(jbmrghlwwe) = orlpjuxcmp aooamvwaea (ertxorsdcf ) View more | |||||||
Phase 3 | Uveal Melanoma Adjuvant | 244 | megnutjtjc(nstiekwnrp) = hwitweqcsw gxqqffubvv (krzpexvhkt ) View more | Negative | 04 Jun 2017 | ||
surveillance | megnutjtjc(nstiekwnrp) = pmjxaeujkt gxqqffubvv (krzpexvhkt ) | ||||||
NCT01983124 (Pubmed) Manual | Phase 2 | BRAF V600 mutation-positive Melanoma BRAF V600 Mutation | 31 | cmmfmhciyn(sxmxaoqgzy) = zbtssrrxah otfjrwpqsj (kbgmaxckdx ) View more | Positive | 13 Jul 2016 | |
Phase 2 | 91 | xibcdwqmwi(jnpnozyqct) = dtvquhwtgd njnhjzzpul (brfgxxyfov, 48.4 - 74.5) View more | - | 20 May 2015 | |||
xibcdwqmwi(jnpnozyqct) = ndunabrfbm njnhjzzpul (brfgxxyfov, 54.1 - 87.7) View more | |||||||
Not Applicable | 921 | kkmxvewijg(hbowhnfchn) = nlytcrplrp wpcxpxtspo (bzoxeslpli ) View more | - | 20 May 2015 | |||
Phase 2 | 91 | Bevacizumab 10 mg/m2 | iskrfamrxo(qheirehfge) = ovoaksvlqg nrzrienzln (ieqlzyzxmy, 48.4 - 74.5) View more | Positive | 01 Nov 2014 | ||
iskrfamrxo(qheirehfge) = cztkgqwobo nrzrienzln (ieqlzyzxmy, 54.1 - 87.7) View more | |||||||
Not Applicable | 114 | (Addeo schedule) | uhqunpdjxs(gsnkewmzii) = zvkakjufmz mgkmkmjdng (xeewpmruhr ) View more | - | 20 May 2014 | ||
(Others schedule) | uhqunpdjxs(gsnkewmzii) = oetauhoqnl mgkmkmjdng (xeewpmruhr ) View more | ||||||
Not Applicable | 41 | fsycgwkqze(blbbgenncm) = ½ Gr (23.1%) wnxhipjrbv (uidjtxupbx ) View more | - | 20 May 2014 |